Efforts to reduce teh value-added tax (VAT) on sunscreen products in Europe have stalled, despite recent appeals from the European parliament. As skin cancer rates rise throughout the continent, some policymakers urged a reclassification of sunscreen from a cosmetic to a pharmaceutical item, aiming to make sun protection more cost‑accessible for the public.
Current VAT Policy on Sunscreen in europe
A formal inquiry from a European parliament representative proposed including sun creams among items eligible for a lower VAT rate, linking the suggestion to recent statistics that identify melanoma as the fourth most diagnosed cancer type in the EU. Presently, sunscreen is labeled as a cosmetic product, wich enforces a minimum VAT rate of 15%.
The official response clarified that discounted VAT is reserved for pharmaceuticals used for medical purposes. Sunscreen, as classified now, does not qualify. The interaction also noted that the 2022 VAT reform resulted from intense negotiations, adn authorities have no intentions of reopening debate or introducing more changes due to the issue’s political complexity.
Ongoing Demand for Cheaper Sun Protection
Interest in revising sun care pricing continues to grow with participation from public health bodies and industry stakeholders. Last year, an international health authority added sun protection products to the essential medicines roster, acknowledging their preventive benefits as melanoma cases rise across the globe.
This reclassification spurred discussion about whether regulatory policies could shift to address high retail prices.Recent consumer surveys indicate that 57% of UK shoppers find sun protection products unaffordable, and 29% said they would use sunscreen daily if costs were lower.
Potential Impact of Regulatory Changes on Product Development
reclassifying sunscreen as a medicinal product could improve affordability, yet it might introduce regulatory obstacles for future SPF development. For example, in one country where sunscreen ingredients fall under drug regulations, the approval of new UV filters stagnated for over two decades. during this time, product formulators leaned on booster agents, which, while increasing effectiveness, also raised questions among consumers about the accuracy of sun care performance claims.
Only recently did the governing authority in that market authorize a new active ingredient for sunscreens-a first since 1999. This slow progression highlighted the contrast with the European approach, where sunscreens are governed as cosmetics, allowing more frequent updates with advanced UV filters.
Although these streamlined European rules have brought more up‑to‑date products to consumers, high prices still present a barrier to everyday sun protection for manny people. The discussion about VAT relief on sunscreen continues, and solutions to make these health-critical products accessible to the whole population are still under debate.
